Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics Thyroid Assays Covered by Independence Blue Cross

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Independence Blue Cross has agreed to cover Interpace's thyroid tests, ThyGeNext and ThyraMir, for patients with thyroid cancer.

Independence covers about 2.5 million individuals in Philadelphia and Southeastern Pennsylvania.

According to Interpace, ThyGenX and ThyraMir combination testing for thyroid cancer can help determine whether initial indeterminate thyroid nodules biopsies are malignant or benign compared to standard clinical practice.

"We are pleased that Independence has established a medical policy and criteria for our molecular thyroid tests, and that these Independence members and their physicians now have cost-effective access to our services," Interpace CEO Jack Stover said in a statement.

In April, Interpace received approval to launch its thyroid tests in New York.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.